34289-60-6

Usage

Uses

Different sources of media describe the Uses of 34289-60-6 differently. You can refer to the following data:
1. 4,6-DiMethyl-2-hydroxypyriMidine Hydrochloride can be used in the preparation of indolizine compounds for use in antifungal combination therapy.
2. 2-Hydroxy-4,6-dimethylpyrimidine hydrochloride was employed in the stereoselective synthesis of meso-N,N′-dicarbethoxy-2,4-diaminopentane and meso-2,4-diaminopentane.

InChI:InChI=1/C6H8N2O.ClH/c1-4-3-5(2)8-6(9)7-4;/h3H,1-2H3,(H,7,8,9);1H

Upstream product

• 57-13-6 urea 
• 123-54-6 acetylacetone 
• 104892-94-6 Phosphorous acid 4,6-dimethyl-pyrimidin-2-yl ester diethyl ester 

Downstream Products

• 947769-31-5 4,6-bis-[2-(4-diphenylamino-phenyl)-vinyl]-pyrimidin-2-ol 
• 1000391-87-6 4,6-bis-[2-(4-diethylamino-phenyl)-vinyl]-pyrimidin-2-ol 
• 1443219-08-6 4,6-bis(2-butoxy-4-(diethylamino)styryl)pyrimidin-2-ol 
• 22746-09-4 4,6-dimethyl-2-(piperazin-1-yl)pyrimidine 
• 4472-44-0 2-chloro-4,6-dimethylpyrimidine 

Relevant academic research and scientific papers

Impact of the anion and chalcogen on the crystal structure and properties of 4,6-dimethyl- 2-pyrimido(thio)nium halides

By the reaction of urea or thiourea, acetylacetone and hydrogen halide (HF, HBr or HI), we have obtained seven new 4,6-dimethyl-2-pyrimido(thio)nium salts, which were characterized by single-crystal X-ray diffraction, namely, 4,6- dimethyl-2-oxo-2,3-dihydropyrimidin-1-ium bifluoride, C6H9N2O+HF2 or (dmpH)F2H, 4,6-dimethyl-2-oxo-2,3-dihydropyrimidin-1-ium bromide, C6H9- N2O+Br or (dmpH)Br, 4,6-dimethyl-2-oxo-2,3-dihydropyrimidin-1-ium iodide, C6H9N2O+I or (dmpH)I, 4,6-dimethyl-2-oxo-2,3-dihydropyrimidin-1-ium iodide-urea (1/1), C6H9N2O+ICH4N2O or (dmpH)Iur, 4,6-dimethyl-2-sulfanylidene- 2,3-dihydropyrimidin-1-ium bifluoride-thiourea (1/1), C6H9N2S+- HF2 CH4N2S or (dmptH)F2Htu, 4,6-dimethyl-2-sulfanylidene-2,3-dihydropyrimidin- 1-ium bromide, C6H9N2S+Br or (dmptH)Br, and 4,6-dimethyl-2- sulfanylidene-2,3-dihydropyrimidin-1-ium iodide, C6H9N2S+I or (dmptH)I. Three HCl derivatives were described previously in the literature, namely, 4,6- dimethyl-2-oxo-2,3-dihydropyrimidin-1-ium chloride, (dmpH)Cl, 4,6-dimethyl- 2-sulfanylidene-2,3-dihydropyrimidin-1-ium chloride monohydrate, (dmptH)- ClH2O, and 4,6-dimethyl-2-sulfanylidene-2,3-dihydropyrimidin-1-ium chloride- thiourea (1/1), (dmptH)Cltu. Structural analysis shows that in 9 out of 10 of these compounds, the ions form one-dimensional chains or ribbons stabilized by hydrogen bonds. Only in one compound are parallel planes present. In all the structures, there are charge-assisted N+ H X hydrogen bonds, as well as weaker CAr + H X and + X interactions. The structures can be divided into five types according to their hydrogen-bond patterns. All the compounds undergo thermal decomposition at relatively high temperatures (150-300 C) without melting. Four oxopyrimidinium salts containing a + X + sandwich-like structural motif exhibit luminescent properties.

Novel 2-alkoxy- and 2-alkylthio-substituted pyrimidines containing 2-(1-methyl-1H-pyrrol-2-yl)vinyl moieties: optical and electrochemical properties

A series of novel Y-shaped dyes bearing the D–π–A–π–D fragment comprising central 2-alkoxy-or 2-alkylthio-substituted pyrimidine core and terminal 2-(1-methyl-1H-pyrrol-2-yl)vinyl moieties have been synthesized and studied as potential materials for the organic electronics. The obtained compounds demonstrated an efficient absorption at ～410 nm with the high molar absorption coefficient (29790–40620 dm3 mol?1 cm?1) and fluorescence emission at ～480 nm (ΦF ～ 7.5–8.6%). Thin films of 2-ethyloxy- or 2-ethylthiopyrimidines exhibited the red-shifted photoluminescence (～600 nm).

Oligomerization of organochlorosilanes in the acetylacetone-carbamide system

Condensation of acetylacetone with carbamide in nonpolar media (benzene, toluene) is initiated by organochlorosilanes. The reaction rapidly occurs under mild conditions to give oligosiloxanes and 4,6-dimethylpyrimidin-2(1H)-one hydrochloride. The conversi

Substituted pyrimidine compound containing isothiourea group and preparation method and application thereof

The invention relates to a substituted pyrimidine compound containing isothiourea perssad and being shown in the formula I and a preparation method and application thereof. The compound is simple in synthesis process, high in efficiency and low in cost. The in-vitro cell test indicates that the substituted pyrimidine compound containing isothiourea perssad has the good anti-tumor effect on HT29, HCT116, A549 and 1299 cells, and the substituted pyrimidine compound containing isothiourea perssad has good cell Golgi apparatus regioselectivity and imaging, can serve as anti-tumor medicine and cell Golgi apparatus fluorescent staining medicine, and has wide application prospects in biomedicine, wherein the formula I is shown in the specification.

Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson’s disease treatment

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra of the human brain, leading to depletion of dopamine production. Dopamine replacement therapy remains the mainstay for attenuation of PD symptoms. Nonetheless, the potential benefit of current pharmacotherapies is mostly limited by adverse side effects, such as drug-induced dyskinesia, motor fluctuations and psychosis. Non-dopaminergic receptors, such as human A2A adenosine receptors, have emerged as important therapeutic targets in potentiating therapeutic effects and reducing the unwanted side effects. In this study, new chemical entities targeting both human A2A adenosine receptor and dopamine D2 receptor were designed and evaluated. Two computational methods, namely support vector machine (SVM) models and Tanimoto similarity-based clustering analysis, were integrated for the identification of compounds containing indole-piperazine-pyrimidine (IPP) scaffold. Subsequent synthesis and testing resulted in compounds 5 and 6, which acted as human A2A adenosine receptor binders in the radioligand competition assay (Ki = 8.7–11.2 μM) as well as human dopamine D2 receptor binders in the artificial cell membrane assay (EC50 = 22.5–40.2 μM). Moreover, compound 5 showed improvement in movement and mitigation of the loss of dopaminergic neurons in Drosophila models of PD. Furthermore, in vitro toxicity studies on compounds 5 and 6 did not reveal any mutagenicity (up to 100 μM), hepatotoxicity (up to 30 μM) or cardiotoxicity (up to 30 μM).

A two-dimensional molecule with a large conjugation degree: Synthesis, two-photon absorption and charge transport ability

A new molecule, 5,5′-bis(4,6-bis((E)-4-(octyloxy)styryl)pyrimidin-2-yl)-2,2′-bithiophene (OSPB), was designed and synthesized. It contains two D-π-A-π-D (donor-π-acceptor-π-donor) segments with an alkoxy group D and a pyrimidine moiety A, and these two segments are connected through a bithiophene moiety to shape a two-dimensional (2D) multibranched conjugated system. The molecule showed high thermal stability. It demonstrated good solubility in THF with an emission maximum at 470 nm, and excimer emission appeared in poor solvents such as aqueous media showing an obvious red-shift. A two-photon excited fluorescence (TPEF) test revealed that the maximal two-photon absorption (2PA) cross-section of the molecule was 1352 GM, which is comparable with the reported bipyrimidine-based multibranched compounds with a stronger donor. Theoretical calculation suggested that the molecule showed good coplanarity made up by two conjugated segments with a small dihedral angle. The charge transport ability of OSPB was preliminarily studied using an organic thin-film transistor (OTFT) device via a low-cost solution processing technique, and the results demonstrated that it was a p-type semiconductor.

2-Amino-1,3,5-triazine chemistry: hydrogen-bond networks, Takemoto thiourea catalyst analogs, and olfactory mapping of a sweet-smelling triazine

Abstract The chemistry of 4,6-dialkyl-2-amino-1,3,5-triazines with bulky alkyl substituents was investigated and their use as building blocks for preparing chiral thiourea organocatalysts explored. Reaction of ammonia with 4,6-di-tert-butyl-2-chloro-1,3,5-triazine gave 4,6-di-tert-butyl-1,3,5-triazin-2-amine which formed extended hydrogen-bond networks in the solid state according to X-ray crystallography. Selected heterocyclic amines were converted to isothiocyanates, and the latter reacted with (S,S)-2-(dimethylamino)cyclohexylamine to give enantiopure 1-hetaryl-3-[2-(dimethylamino)cyclohexyl]thioureas, with hetaryl representing either 4,6-dimethyl-1,3-diazin-2-yl, 4,6-diisopropyl-1,3,5-triazin-2-yl, or 4,6-di-tert-butyl-1,3,5-triazin-2-yl groups. These compounds are structural analogs of Takemotos's chiral thiourea organocatalysts (1-[3,5-bis(trifluoromethyl)phenyl]-3-[(1S,2S)-2-(dimethylamino)cyclohexyl]thiourea) with an aza-aryl instead of the 3,5-bis(trifluoromethyl)phenyl group. They feature a strong intramolecular N-H to N-1 hydrogen bond, as shown by X-ray crystallography of 1-(4,6-di-tert-butyl-1,3,5-triazin-2-yl)-3-[2-(dimethylamino)cyclohexyl]thiourea in the solid state and by 1H NMR spectroscopy of all derivatives in CDCl3 solution, which prevents them from acting as bifunctional organocatalyst. In the reaction of 4,6-di-tert-butyl-2-chloro-1,3,5-triazine with ammonia, 4,6-di-tert-butyl-2-ethoxy-1,3,5-triazine was identified as side-product displaying a mildly sweet, floral odor that is unusual for a 1,3,5-triazine. Analogs (>35) of 4,6-di-tert-butyl-2-ethoxy-1,3,5-triazine were prepared to define the important structural factors of the olfactophore.

Synthesis and characterization of new 2-pyrimidyl chalcogen (S, Se, Te) compounds: X-ray crystal structure of bis(4,6-dimethyl-2-pyrimidyl)diselenide and 4,6-dimethyl-2-(phenylselanyl)pyrimidine

New and synthetically important symmetrical bis(4,6-dimethyl-2-pyrimidyl) dichalcogenides have been synthesized by reacting 4,6-dimethyl-2- chloropyrimidine with the corresponding dichalcogenide (E2 2- where E = S, Se, Te) ion. The u

Synthesis of a novel series of (E, E)-4,6-bis(styryl)-2-O-glucopyranosyl- pyrimidines and their potent multidrug resistance (MDR) reversal activity against cancer cells

A novel series of methoxy or benzyloxy substituted (E,E)-4,6-bis(styryl)-2- O-glucopyranosyl-pyrimidines as curcuminoid analogs were synthesized in four steps with total yields of 21.5% to 33.9%. A549 and HL60 cells were employed for the anticancer activity testing. The results demonstrated that 5a, 5c, and 5e have some inhibitory activity against the HL-60 cell line. Unfortunately, no compound displayed inhibitory activity against A549 except for 5c. MDR reversal activity results demonstrated that compounds 4a (RF = 12.3) and 4b (RF = 18.5) showed strong reversal activity to the P-gp-mediated LCC6MDR cells compared to verapamil (RF = 3.2) and no cytotoxicity to cancer or normal cell lines even at a high concentrations (100M).

2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.